Cargando…
Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective
Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes the consensus managem...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139291/ https://www.ncbi.nlm.nih.gov/pubmed/32121063 http://dx.doi.org/10.3390/cancers12030554 |
_version_ | 1783518731948785664 |
---|---|
author | Naseri, Simon Steiniche, Torben Ladekarl, Morten Bønnelykke-Behrndtz, Marie Louise R. Hölmich, Lisbet W. Langer, Seppo Venzo, Alessandro Tabaksblat, Elizaveta Klausen, Siri Skaarup Larsen, Mathilde Junker, Niels Chakera, Annette H. |
author_facet | Naseri, Simon Steiniche, Torben Ladekarl, Morten Bønnelykke-Behrndtz, Marie Louise R. Hölmich, Lisbet W. Langer, Seppo Venzo, Alessandro Tabaksblat, Elizaveta Klausen, Siri Skaarup Larsen, Mathilde Junker, Niels Chakera, Annette H. |
author_sort | Naseri, Simon |
collection | PubMed |
description | Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes the consensus management recommendations developed by the Danish MCC expert group and is based on a systematic literature search. Patients with localized disease are recommended surgical excision and adjuvant radiotherapy to the primary site; however, this may be omitted in patients with MCC with low risk features. Patients with regional lymph node involvement are recommended complete lymph node removal and adjuvant radiotherapy in case of extracapsular disease. Metastatic disease was traditionally treated with chemotherapy, however, recent clinical trials with immune therapy have been promising. Immune checkpoint inhibitors targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) axis should therefore be strongly considered as first-line treatment for fit patients. A 5-year follow-up period is recommended involving clinical exam every 3 months for 2 years and every 6 months for the following 3 years and PET-CT one to two times a year or if clinically indicated. These national recommendations are intended to offer uniform patient treatment and hopefully improve prognosis. |
format | Online Article Text |
id | pubmed-7139291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71392912020-04-10 Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective Naseri, Simon Steiniche, Torben Ladekarl, Morten Bønnelykke-Behrndtz, Marie Louise R. Hölmich, Lisbet W. Langer, Seppo Venzo, Alessandro Tabaksblat, Elizaveta Klausen, Siri Skaarup Larsen, Mathilde Junker, Niels Chakera, Annette H. Cancers (Basel) Review Merkel cell carcinoma (MCC) is a rare malignant neuroendocrine carcinoma of the skin with a poor prognosis and an apparent increase in incidence. Due to its rarity, evidence-based guidelines are limited, and there is a lack of awareness among clinicians. This review constitutes the consensus management recommendations developed by the Danish MCC expert group and is based on a systematic literature search. Patients with localized disease are recommended surgical excision and adjuvant radiotherapy to the primary site; however, this may be omitted in patients with MCC with low risk features. Patients with regional lymph node involvement are recommended complete lymph node removal and adjuvant radiotherapy in case of extracapsular disease. Metastatic disease was traditionally treated with chemotherapy, however, recent clinical trials with immune therapy have been promising. Immune checkpoint inhibitors targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) axis should therefore be strongly considered as first-line treatment for fit patients. A 5-year follow-up period is recommended involving clinical exam every 3 months for 2 years and every 6 months for the following 3 years and PET-CT one to two times a year or if clinically indicated. These national recommendations are intended to offer uniform patient treatment and hopefully improve prognosis. MDPI 2020-02-28 /pmc/articles/PMC7139291/ /pubmed/32121063 http://dx.doi.org/10.3390/cancers12030554 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Naseri, Simon Steiniche, Torben Ladekarl, Morten Bønnelykke-Behrndtz, Marie Louise R. Hölmich, Lisbet W. Langer, Seppo Venzo, Alessandro Tabaksblat, Elizaveta Klausen, Siri Skaarup Larsen, Mathilde Junker, Niels Chakera, Annette H. Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title | Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title_full | Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title_fullStr | Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title_full_unstemmed | Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title_short | Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective |
title_sort | management recommendations for merkel cell carcinoma—a danish perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139291/ https://www.ncbi.nlm.nih.gov/pubmed/32121063 http://dx.doi.org/10.3390/cancers12030554 |
work_keys_str_mv | AT naserisimon managementrecommendationsformerkelcellcarcinomaadanishperspective AT steinichetorben managementrecommendationsformerkelcellcarcinomaadanishperspective AT ladekarlmorten managementrecommendationsformerkelcellcarcinomaadanishperspective AT bønnelykkebehrndtzmarielouise managementrecommendationsformerkelcellcarcinomaadanishperspective AT rholmichlisbet managementrecommendationsformerkelcellcarcinomaadanishperspective AT wlangerseppo managementrecommendationsformerkelcellcarcinomaadanishperspective AT venzoalessandro managementrecommendationsformerkelcellcarcinomaadanishperspective AT tabaksblatelizaveta managementrecommendationsformerkelcellcarcinomaadanishperspective AT klausensiri managementrecommendationsformerkelcellcarcinomaadanishperspective AT skaaruplarsenmathilde managementrecommendationsformerkelcellcarcinomaadanishperspective AT junkerniels managementrecommendationsformerkelcellcarcinomaadanishperspective AT chakeraannetteh managementrecommendationsformerkelcellcarcinomaadanishperspective |